Carl Regillo, MD
Enriched profileChief, Retina Service, Wills Eye Hospital; Professor of Ophthalmology, Sidney Kimmel Medical College at Thomas Jefferson University · Sidney Kimmel Medical College at Thomas Jefferson University
Carl Regillo is Chief, Retina Service, Wills Eye Hospital; Professor of Ophthalmology, Sidney Kimmel Medical College at Thomas Jefferson University at Sidney Kimmel Medical College at Thomas Jefferson University. OpenAlex indexes 407 publications with 14,493 citations (h-index 58); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 31 Aug 2026
Carl Regillo, MD, is Chief, Retina Service, Wills Eye Hospital at Sidney Kimmel Medical College at Thomas Jefferson University / Wills Eye Hospital. The public record shows 407 publications with 14,493 citations (h-index 58), centered on Retinal Diseases and Treatments, Retinal and Macular Surgery, Intraocular Surgery and Lenses. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 38 companies.
- Most recent indexed publication: 2026 · Journal of vitreoretinal diseases
- Top research focus: Retinal Diseases and Treatments
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 38 companies
Generated from the cited public record · current as of 31 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 3 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 177.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 31 Aug 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
Sponsor: OcuTerra Therapeutics, Inc.
Industry payments
Updated 31 Aug 2026
38 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Apellis Pharmaceuticals, Inc.Program year20257 payments$22,019openpaymentsdata.cms.gov ↗
- Astellas Pharma Global DevelopmentProgram year20255 payments$11,342openpaymentsdata.cms.gov ↗
- Genentech USA, Inc.Program year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
78.4%Antineovascularisation agents69.9%Faricimab-svoa100%Part B, office-administered≥75 patientsComplement Inhibitor8%Avacincaptad pegol100%Part B, office-administered≥43 patientsCancer & immunology
18.9%Complement Inhibitor12.7%Pegcetacoplan100%Part B, office-administered≥53 patientsVascular Endothelial Growth Factor Inhibitor6.2%Aflibercept99%Eylea1%Part D + Part B<11 patientsDermatology
2.6%Corticosteroid2.6%Triamcinolone acetonide100%Part B, office-administered≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 31 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Real-World Safety of Intravitreal Complement Inhibitor Avacincaptad Pegol for Geographic Atrophy.
Journal of vitreoretinal diseases
Article2026 - Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study.
Eye (London, England)
Article2026 - TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.
Eye (London, England)
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)Network
Updated 31 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 31 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/carl-regillo-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/carl-regillo-md-0364a24
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Carl-Regillo-2158251123
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/willseyehospital/posts/watch-dr-carl-regillo-chief-of-the-retina-service-at-wills-eye-hospital-shares-g/1156144899852443
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/p/DNjsAKASzWl
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Instagram
instagram.com/wills_eye/reel/DA1PtYWNxwy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 31 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinasociety.org ↗
- Scientific editorial board
American Journal of Ophthalmology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗ - Scientific editorial board
Review of Ophthalmology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →midatlanticretina.com ↗
- Wills Eye Surgical Network - Main Line
100 Presidential Blvd., Suite 200, Bala Cynwyd, PA 19004 (additional practice location)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- touchOPHTHALMOLOGY conference interview
Hawaiian Eye and Retina 2023, "New and emerging treatments for neovascular age-related macular degeneration"
2023provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →touchophthalmology.com ↗ - PeerView CME Podcast/Video
"Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic Retinopathy"
2021provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore